Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. These consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities summarize the latest WHO recommendations on TB and key comorbidities. ...
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released in 2018 ...
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with Leis...
Leishmaniasis, Visceral/etiology,
Drug Therapy, Combination,
HIV Infections/complications,
Anti-Retroviral Agents/therapeutic use,
Africa, Eastern,
Asia, Southeastern,
Anthelmintics/therapeutic use,
Leishmaniasis, Visceral/drug therapy,
Coinfection/complications
The World Health Organization’s (WHO’s) strategy for tuberculosis (TB) prevention, care and control for 2015–2035 (known as the End TB Strategy) prioritizes the early diagnosis of TB. This prioritization includes cases of smear-negative disease, which are often associated with coinfection with HIV ...
These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic hepatitis C infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 20...
Hepatitis C, Chronic/complications,
Hepatitis C, Chronic/drug therapy,
HIV Infections/complications,
Hepatitis C, Chronic/diagnosis,
Coinfection,
Antiviral Agents/administration & dosage,
Drug Therapy, Combination
Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection...
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities t...
Nahid, P;
Dorman, SE;
Alipanah, N;
Barry, PM;
Brozek, JL;
Cattamanchi, A;
Chaisson, LH;
Chaisson, RE;
Daley, CL;
Grzemska, M;
Higashi, JM;
Ho, CS;
Ho, CS;
Hopewell, PC;
Keshavjee, SA;
Lienhardt, C;
Menzies, R;
Merrifield, C;
Narita, M;
O'Brien, R;
Peloquin, CA;
Raftery, A;
Saukkonen, J;
Schaaf, HS;
Sotgiu, G;
Starke, JR;
Migliori, GB;
Vernon, A.
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tube...
Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have
emerged as potential point-of-care tests for tuberculosis (TB). LAM antigen is a lipopolysaccharide
present in mycobacterial cell walls, which is released from metabolically active or degenerating
bacterial cells ...
The World Health Organization (WHO) first published guidance for national
tuberculosis control programmes on managing tuberculosis in children (hereafter
called “the Guidance”) in 2006. The Guidance follows the principles of a public
health approach aimed at optimizing outcomes, including the quality...
